- Home
- DALN vs BIVI Comparison
DALN vs BIVI Comparison
Compare DALN & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DALN
- BIVI
- Stock Information
- Founded
- DALN 1954
- BIVI 2013
- Country
- DALN United States
- BIVI United States
- Employees
- DALN N/A
- BIVI N/A
- Industry
- DALN Newspapers/Magazines
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- DALN Consumer Discretionary
- BIVI Health Care
- Exchange
- DALN Nasdaq
- BIVI Nasdaq
- Market Cap
- DALN 22.1M
- BIVI 20.4M
- IPO Year
- DALN 2008
- BIVI N/A
- Fundamental
- Price
- DALN $4.69
- BIVI $3.36
- Analyst Decision
- DALN
- BIVI Strong Buy
- Analyst Count
- DALN 0
- BIVI 2
- Target Price
- DALN N/A
- BIVI $40.00
- AVG Volume (30 Days)
- DALN 16.6K
- BIVI 11.7M
- Earning Date
- DALN 11-01-2024
- BIVI 11-06-2024
- Dividend Yield
- DALN 13.65%
- BIVI N/A
- EPS Growth
- DALN N/A
- BIVI N/A
- EPS
- DALN N/A
- BIVI N/A
- Revenue
- DALN $131,645,000.00
- BIVI N/A
- Revenue This Year
- DALN N/A
- BIVI N/A
- Revenue Next Year
- DALN N/A
- BIVI N/A
- P/E Ratio
- DALN N/A
- BIVI N/A
- Revenue Growth
- DALN N/A
- BIVI N/A
- 52 Week Low
- DALN $2.98
- BIVI $1.04
- 52 Week High
- DALN $4.80
- BIVI $58.20
- Technical
- Relative Strength Index (RSI)
- DALN 64.60
- BIVI 75.86
- Support Level
- DALN $4.28
- BIVI $1.09
- Resistance Level
- DALN $4.80
- BIVI $7.50
- Average True Range (ATR)
- DALN 0.17
- BIVI 0.60
- MACD
- DALN 0.05
- BIVI 0.28
- Stochastic Oscillator
- DALN 85.86
- BIVI 35.61
About DALN DallasNews Corporation Series A
DallasNews Corp is a local news and information publishing company in Texas with commercial printing, distribution, and direct mail capabilities, as well as a presence in emerging media and digital marketing.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.